AHRQ Comparative Study Agenda Should Emphasize Lit Reviews – McClellan
Executive Summary
The federal government's investment in comparative effectiveness research for drugs should emphasize literature reviews and other alternatives to clinical trials, Centers for Medicare & Medicaid Services Administrator Mark McClellan said
You may also be interested in...
AHRQ Drug Effectiveness Comparisons Will Focus On 10 “Priority Conditions”
Prescription drug comparative effectiveness research will proceed for 10 "priority conditions," thanks to $15 mil. provided by the fiscal year 2005 omnibus appropriations bill, the Agency for Healthcare Research & Quality said Dec. 15
AHRQ Drug Effectiveness Comparisons Will Focus On 10 “Priority Conditions”
Prescription drug comparative effectiveness research will proceed for 10 "priority conditions," thanks to $15 mil. provided by the fiscal year 2005 omnibus appropriations bill, the Agency for Healthcare Research & Quality said Dec. 15
Pfizer, Novartis Learning The VALUE Of Comparative Research
A Novartis-sponsored study comparing Diovan to Pfizer's Norvasc highlights the risk firms take in conducting comparative research